Century Therapeutics Inc (IPSC) is a Healthcare · Biotechnology company listed on NASDAQ. Price $1.85 (-1.60%), Market cap $0.42B, 52-week low–high $0.46 ~ $2.94.
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-
Financial statements, price targets, institutional (13F) holdings and related news for Century Therapeutics Inc are updated in real time on BlackAll Trade.
Century Therapeutics Inc trades at $1.85 (-1.60%). Real-time quotes and charts are available on BlackAll Trade.
Century Therapeutics Inc has a market cap of about $0.42B.
Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its